Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer Patients

11 Feb 2025

Abstract excerpt

PURPOSE: Plasma-based liquid biopsy tests can detect tumor-specific genetic alterations and offer many advantages that complement tissue-based comprehensive genomic profiling. However, age-related clonal hematopoiesis (CH) mutations can confound liquid biopsy results and potentially lead to incorrect therapy choice. EXPERIMENTAL DESIGN: We assessed the landscape of 16,812 liquid profiles across 49 cancer types...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39932457
DOI: 10.1158/1078-0432.ccr-24-3335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer PatientsPMID 39932457Read ↗

Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsySemantic proximity Read ↗

Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations.Semantic proximity Read ↗

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA SamplesSemantic proximity Read ↗

Cell-Free DNA, Tumor Molecular Concordance, and Clinical Correlates of Patients with Cancer Treated in a Large Community Health Care NetworkSemantic proximity Read ↗

plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis-Derived Variants in Liquid Biopsies from Patients with Solid Tumors.Semantic proximity Read ↗

A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)Semantic proximity Read ↗

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assaySemantic proximity Read ↗

Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.Semantic proximity Read ↗

Exome sequencing of 628,388 individuals identifies common and rare variant associations with clonal hematopoiesis phenotypesSemantic proximity Read ↗

Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity Read ↗

AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncologySemantic proximity Read ↗

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.